G. Hughes

发表

Analogues of capsaicin with agonist activity as novel analgesic agents: structure-activity studies. 4. Potent, orally active analgesics.

S. Bevan, R. Wrigglesworth, J. Winter, 1996, Journal of medicinal chemistry.

Bradyzide, a potent non‐peptide B2 bradykinin receptor antagonist with long‐lasting oral activity in animal models of inflammatory hyperalgesia

P. McIntyre, R. Wrigglesworth, C. Snell, 2000, British journal of pharmacology.

AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2.

R. Pehrson, Yafeng Xue, F. Narjes, 2021, Journal of medicinal chemistry.

Design of non-peptide CCK2 and NK1 peptidomimetics using 1-(2-nitrophenyl)thiosemicarbazide as a novel common scaffold.

R. Wrigglesworth, C. Snell, J. Wood, 2001, Bioorganic & medicinal chemistry letters.

The discovery of capsazepine, the first competitive antagonist of the sensory neuron excitants capsaicin and resiniferatoxin.

J. Davies, S. Bevan, J. Winter, 1994, Journal of medicinal chemistry.

2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N - methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models.

S. Ko, L. Urbán, M. Lemaire, 1998, Journal of medicinal chemistry.

Novel, potent antagonists of capsaicin

G. Hughes, 2005 .

Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin

H P Rang, S. Bevan, H. Rang, 1992, British journal of pharmacology.

Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

Paul J. Groot-Kormelink, D. Rowlands, H. Danahay, 2021, Journal of medicinal chemistry.

Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core.

P. McIntyre, S. Bevan, T. Ritchie, 2004, Journal of medicinal chemistry.

Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain.

P. McIntyre, S. Bevan, A. Dyson, 2006, Journal of medicinal chemistry.